Expression ratio of circular to linear ANRIL in hypertensive patients with coronary artery disease

Abstract

Atherosclerotic lesions of the coronary arteries are still in charge of significant annual morbidity and mortality despite intense therapeutic advancements. Genome-born elements contribute substantially to the atherosclerosis process. ANRIL is one of the long non-coding RNAs with outstanding functions particularly regulation of genes involved in atherosclerosis development. In this study, we measured ANRIL expression (circular-, linear-, and circular/linear ratio) in hypertensive patients with coronary artery disease (CAD) compared with peers without CAD. Among hypertensive patients who were candidates of angiography, 25 subjects with CAD and the equal number without CAD were considered as the case and control groups, respectively. Different categories of data were recorded through a predefined questionnaire. Before angiography, blood samples were obtained. After RNA extraction and cDNA synthesis, quantitative PCR was performed using specific primers for circular and linear ANRIL. Age and gender were not different between the groups. Most of the parameters of the lipid profile besides creatinine and blood urea nitrogen were remarkably worse in the case group. Circular ANRIL was significantly lower in the case group while linear counterparts were significantly higher in this group. Circular/linear ratio was also significantly lower in the case group. To overcome growing devastating trend of CAD, scrutinizing different factors involved in the initiation and development of atherosclerosis is a must. Atheroprotective role of circular ANRIL and atheroprogressive role of linear ANRIL were shown in our patients with hypertension.

Evolution of the search for a common mechanism of congenital risk of coronary heart disease and type 2 diabetes mellitus in the chromosomal locus 9p21.3

“…The regulation of the balance depends on the cell type and context, however, there is still no sufficient data on the molecular coordinator of the ratio of linear and circular isoforms, and it is not known whether inhibition of linear ANRIL isoforms is sufficient to protect against CHD and DM2. [ 30 ] Perhaps this special influence of ANRIL can also explain the paradox when the genes involved in the biology of traits show different effects. Genetic variants can disrupt ANRIL, which mechanically links CHD to DM2.…”

lncRNA CDKN2B-AS1 is downregulated in patients with ventricular fibrillation in acute myocardial infarction

“…CDKN2B-AS1 plays a vital role in cell proliferation, aging, inflammation, apoptosis and also as a tumor suppressor [ 34 , 35 ]. In the field of cardiovascular disease, CDKN2B-AS1 has been associated with atherosclerotic vascular disease, coronary artery disease, stroke, aortic aneurysm, and myocardial infarction [ 36 ]. Vausort et al [ 13 ] showed that patients with ST-segment-elevation AMI had significant lower levels of CDKN2B-AS1 than patients with NSTEMI (P<0.001).…”

The Long Non-Coding RNA ANRIL in Cancers

“…CircRNAs can act as competitive endogenous RNA (ceRNA) by sequestering one or multiple RNA-binding proteins (RBP) or miRNAs [ 82 ]. Analysis of the ratio between circular and linear ANRIL isoforms within a cohort of patients with CVD and melanoma revealed a significant difference compared to the control groups [ 78 , 83 ]. In addition, Holdt and colleagues discovered a circANRIL, which exhibits anti-atherosclerotic properties by sequestrating PES1, a factor involved in the assembly of the 60S ribosomal subunit.…”